Benzhydrocodone - Zevra Therapeutics
Alternative Names: KP-201; KP201/IR (acetaminophen-free); KP201/IR (APAP-free)Latest Information Update: 26 Feb 2023
At a glance
- Originator KemPharm
- Developer Zevra Therapeutics
- Class Benzoates; Epoxy compounds; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute pain
Most Recent Events
- 22 Feb 2023 KemPharm is now called Zevra Therapeutics
- 31 Dec 2022 USPTO issues 14 composition-of-matter or method of treatment patents covering benzhydrocodone before December 2022
- 31 Dec 2022 Zevra Therapeutics has compositions-of-matter patents covering benzhydrocodone in Australia, Canada, Chile, China, Israel, Mexico, South Africa, and South Korea